Clinically exposed area lacking effective treatment

Sepsis is a common and serious and emergency condidtion that develops as a strong reaction to infection by the immune system. As a defence, the immune system emits a series of inflammatory and anti-inflammatory substances, which loses control and becomes counterproductive, giving rise to negative circulation control. This results in low blood pressure and a reduced supply of oxygen to vital organs. Sepsis can produce life-threatening damage to organs, and if the infection is not controlled the condition can deteriorate further by the formation of blood clots in blood vessels. At present, health providers do not have effective treatment to reduce the risk for organ damage, and medical requirements are extensive.

Multi-billion dollar market with high mortality rates

Sepsis is estimated to be the third largest cause of death globally. Patients that develop sepsis have a high mortality rate of 20-50%. Severe sepsis or septic shock have mortality rates of up to 80%. Currently, there is no drug treatment available for these vulnerable patients to tackle the life-threatening condition arising as a result of the interaction between coagulation and inflammation systems. Typically, patients are given supportive treatment and antibiotics. The critical condition and the high level of clinical support required imparts large economic consequences. In the US alone, the cost is estimated at USD 14.6 billion per year. Aptahem considers that the market for emergency preventive drugs to improve survival rates among these patients is significant. Apta-1 is therefore being developed to meet this clinical requirement.